Theranova (dialysis membrane)

2020: The announcement of Theranova - the high-selection dialysis membrane

At the end of August, 2020 the Baxter company released a new dialysis membrane of Theranova. According to the press release, Theranova it is intended for performing expanded hemodialysis therapy and allows to filter broader range of a molecule of blood, than traditional filters for a hemodialysis. In particular, a new system allows to delete from a blood-groove the certain molecules connected with inflammation and cardiovascular diseases at patients with a renal failure.

Baxter provided the high-selection dialysis membrane

The expanded hemodialysis is carried out to similarly standard procedure, but uses other dialysis membrane, allowing to achieve more good results. So, the membrane of Theranova combines high-permeability and selectivity concerning uraemic toxins, but does not pass the main proteins and provides the high level of albumine in blood during treatment. The CEO of division on treatment of diseases of kidneys of Baxter Gavin Campbell noted that expanded dialysis is already carried out in more than 40 countries with excellent results worldwide.

Baxter conducted randomized controlled study in the USA to estimate security and efficiency of Theranova at patients from terminal HBP. Within the research within 24 weeks 172 hemodialysis patients at whose treatment used either a new dialysis membrane (Theranova 400), or a dialysis membrane with high capacity (ELISIO-17H) were observed. The research showed that use of Theranova 400 allows to delete from a molecule blood-groove which as it is supposed, make the contribution to development of cardiovascular diseases at a terminal stage of a disease of kidneys. Specialists hope that application of a new membrane will allow to slow down progressing of these defeats and to prolong life to patients.^[1]

Notes